Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 8 de 8
Filter
1.
J Diabetes Metab Disord ; 17(2): 345-355, 2018 Dec.
Article in English | MEDLINE | ID: mdl-30918870

ABSTRACT

BACKGROUND: Hyperthyroidism is a systemic disorder that causes severe morbidity and is even fatal. Several studies have been performed in Iran to determine the epidemiologic properties of hyperthyroidism; however, they did not use a systematic approach or meta-analysis to evaluate the results. Therefore, this systematic review and meta-analysis aimed to evaluate the epidemiologic data on hyperthyroidism in Iran. METHODS: In order to find all relevant papers published by October 2017, we searched both international (Web of Science, Scopus, PubMed, Embase, and Cochrane library) and Persian databases (Scientific Information Database, Magiran, and Barekat Knowledge Network System). Meta-analysis was performed using metaprop random effects analysis for prevalence and metaprop fix effect analysis for incidence by Stata statistical software. I2 was used for the demonstration of heterogeneity. RESULTS: Of 7667 published papers or conference proceeding, 7448 studies were removed after eliminating duplicates and reviewing titles/abstracts. Finally, after reviewing 219 full texts, 18 papers met the inclusion and exclusion criteria. The pooled prevalence of total, overt, and subclinical hyperthyroidism in general population were 2.43% (95% CI: 0.23-4.63%), 0.69% (95% CI: 0.21-1.18%), and 1.52% (95% CI: 0.14-2.89%), respectively. The pooled annual incidence of total hyperthyroidism was 2.2 (95% CI: 1.1-3.3) per 1000 population: 0.8 (0.1-1.4) and 1.3 (0.4-2.2) per 1000 population for overt and subclinical hyperthyroidism, respectively. CONCLUSIONS: This is the first systematic review and meta-analysis, which investigated the epidemiology of hyperthyroidism in Iran. It seems that the prevalence and incidence of hyperthyroidism among the general population in Iran is similar to that in other parts of the world.

2.
BMJ Open ; 7(8): e013606, 2017 Aug 04.
Article in English | MEDLINE | ID: mdl-28780537

ABSTRACT

INTRODUCTION: Musculoskeletal disorders and cognitive diseases are prevalent, and they are significant determinants of morbidity and mortality in older adults. The aim of this study is to investigate the prevalence of musculoskeletal and cognitive diseases and their risk factors and also to assess their associations during future follow-ups. METHODS AND ANALYSIS: Bushehr Elderly Health (BEH) programme is a population-based prospective cohort study being conducted in Bushehr, a southern province of Iran. A total of 3000 older people aged ≥60 years participated in the first stage from which 2772 were eligible to participate in the second stage, which started after 2.5 years. Data including demographic status, lifestyle factors, general healthandmedical history, and mentalandfunctional health are collected through a questionnaire. Anthropometric measures, performance testsandmuscle strength, blood pressure and and body composition measurements are done. A total 25 cc venous blood is taken, and sera are stored at -80°C for possible future analyses. ETHICS AND DISSEMINATION: The study protocol was approved by the ethics committee of Endocrinology and Metabolism Research Institute, affiliated to Tehran University of Medical Science as well as the Research Ethics Committee of Bushehr University of Medical Sciences. A written informed consent was signed by all the participants. The study findings will show the prevalence of musculoskeletal disease, cognitive impairment and their risk factors in an elderly population. The participants will be followed during the study to measure the occurrence outcomes.This study will also have the potential to inform the development of beneficial interventions to improve the management of musculoskeletal and cognitive impairment in Iran and other countries in the Middle East.Our findings will be disseminated via scientific publication as well as presentation to stakeholders, including the patients, clinicians, the public and policymakers, via appropriate avenues.


Subject(s)
Health Services for the Aged/standards , Patient Discharge/standards , Quality Improvement/standards , Research Design , Stroke/epidemiology , Stroke/therapy , Aged , Aged, 80 and over , Cognitive Dysfunction/diagnosis , Cognitive Dysfunction/epidemiology , Female , Follow-Up Studies , Genetic Testing , Humans , Iran/epidemiology , Life Style , Male , Musculoskeletal Diseases/diagnosis , Musculoskeletal Diseases/epidemiology , Physical Examination , Pilot Projects , Policy Making , Prospective Studies , Risk Factors , Serologic Tests , Stroke/physiopathology , Stroke/psychology , Surveys and Questionnaires
3.
Article in English | MEDLINE | ID: mdl-26246012

ABSTRACT

Osteoporosis diagnosis, which is nowadays generally made based on bone mineral density (BMD) measurements, suffers from certain limitations. Thus it is believed that bone turnover markers (BTMs) can help improve osteoporosis detection. The shifting interest toward this topic made us perform a review to gather information on existing markers and their role in osteoporosis diagnosis. Based on the results, in this review, a list of existing markers and some of their characteristics is provided. Moreover, a brief explanation of different types of variability met while using these markers is also described. Finally some of the patents provided for the diagnosis of these markers are presented. While the use of BTMs in osteoporosis diagnosis has certain advantages over BMD and clinical risk assessment tools, more studies are needed before they can be used as a separate tool in this regard. It could be concluded that despite the fact that BTMs are better than BMD not only in monitoring treatment but also in identifying those at-risk, the diagnostic value of BTMs in predicting osteoporosis is low, and thus a model is needed to assess several BTMs at the same time with higher accuracy and lower variability to overcome this limitation.


Subject(s)
Biomarkers/blood , Bone Remodeling , Osteoporosis/diagnosis , Alkaline Phosphatase/blood , Bone Density , Collagen Type I/blood , Humans , Osteocalcin/blood , Peptide Fragments/blood , Peptides/blood , Procollagen/blood
4.
Daru ; 22: 62, 2014 Sep 16.
Article in English | MEDLINE | ID: mdl-25223378

ABSTRACT

BACKGROUND: In spite of several studies, the impact of homocysteine level and folic acid supplementation on bone metabolism is yet to be recognized. In this registered clinical trial (IRCT2014042217385N1), we aimed to find out the power of 6-month folic acid supplementation on homocysteine level and bone metabolism. METHODS: Forty postmenopausal osteoporotic women (50 to 87 years) were enrolled in the study. All participants were randomized to receive folic acid 1 mg (n = 17) or placebo (n = 14). At baseline, 3 months, and finally 6 months post intervention, the level of homocysteine, vitamin B12, and bone biomarkers were measured. RESULTS: Both groups were similar at baseline. The homocysteine decreased in both groups but statistically non-significant (P > 0.05). The changes of the serum level of vitamin B12, osteocalcin, and ß cross laps were significant between groups after 6 months (P ≤ 0.05). CONCLUSION: The trend of changes of bone biomarkers after 6 months folic acid supplementation shows that homocysteine concentration and/or folic acid supplementation have impact on the rate of bone metabolism. However, further investigations by larger sample size and differentiating age and gender are still needed to clarify the exact role of folate, homocysteine and vitamin B12.


Subject(s)
Bone and Bones/metabolism , Folic Acid/administration & dosage , Homocysteine/metabolism , Osteoporosis, Postmenopausal/drug therapy , Vitamin B Complex/administration & dosage , Aged , Aged, 80 and over , Biomarkers/blood , Biomarkers/urine , Dietary Supplements , Double-Blind Method , Female , Folic Acid/pharmacology , Humans , Middle Aged , Osteoporosis, Postmenopausal/blood , Osteoporosis, Postmenopausal/urine , Vitamin B Complex/pharmacology
5.
J Spinal Cord Med ; 37(6): 744-50, 2014 Nov.
Article in English | MEDLINE | ID: mdl-24621041

ABSTRACT

OBJECTIVES: We described the associations between demographic and injury-related factors on bone mineral density (BMD) of the spine and the hip among adult patients with chronic spinal cord injury (SCI). DESIGN: BMD in spinal and femoral bone sites were assessed. Multivariate analysis was performed to evaluate the relationship between anthropometric and injury-related factors with BMD. Serum level and amount of dietary intake of calcium, phosphor, and 25-hydroxy vitamin D were measured. SETTING: A referral tertiary rehabilitation center in Iran. PARTICIPANTS: Patients with SCI who had no previous history of endocrine disorders and were not on specific medications entered the investigation. Those with non-traumatic SCI, pregnant, or with substance dependency were excluded as well. INTERVENTIONS: No interventions were applied. MAIN STUDY OUTCOME MEASURES: Dual X-ray absorptiometry was performed to estimate BMD. Body mass index was positively associated with higher femoral (P < 0.01, r = 0.56) and hip (P < 0.0001, r = 0.82) BMD only in female participants. The high prevalence of vitamin D deficiency (60%) was noticeable. RESULTS: Older male patients revealed lower BMD only in spinal vertebrae (P < 0.02, r = -0.21). A significant higher BMD loss in lumbar vertebras in male patients with complete spinal cord lesion (P < 0.009) was detected. Spinal reduction of BMD was more severe when the level of injury was above T6 (P < 0.02). CONCLUSION: Along with the clarification of age, gender, post injury duration, and the other factors' effect on the BMD in the SCI patients, here we have also shown the noticeable prevalence of the 25-hydoxy vitamin D deficiency in these patients which needs attention.


Subject(s)
Bone Density , Bone Diseases/etiology , Spinal Cord Diseases/complications , Absorptiometry, Photon , Adolescent , Adult , Aged , Analysis of Variance , Anthropometry , Body Mass Index , Bone Diseases/blood , Chronic Disease , Female , Humans , Iran/epidemiology , Male , Middle Aged , Neurologic Examination , Sex Factors , Spinal Cord Diseases/blood , Vitamin D/blood , Young Adult
6.
J Diabetes Metab Disord ; 12(1): 3, 2013 Jan 08.
Article in English | MEDLINE | ID: mdl-23497585

ABSTRACT

"Invasive giant prolactinoma" is a large prolactinoma (>4 cm in dimension) presenting with serum prolactin levels of >1000 ng/dL and mass related clinical symptoms. Here we report a patient with a giant prolactinoma presented with central hypogonadism, suppressed adrenal and thyroid function, supra sellar extension, visual field impairment and high prolactin level.The patient was treated with cabergoline, levothyroxin and prednisolone. After 18 months, tumor size markedly reduced, associated with adrenal function and visual field improvement, but central hypogonadism and secondary hypothyroidism persisted.Previous studies showed normalization of thyrotropin secretion after treatment but it remained low in our patient even after 18 months follow up.

7.
J Res Med Sci ; 17(4): 322-7, 2012 Apr.
Article in English | MEDLINE | ID: mdl-23267391

ABSTRACT

BACKGROUND: Clinical studies have reported that osteoporosis after spinal cord injury (SCI) can be the inflammation-induced base condition and n-3 polyunsaturated fatty acids (PUFAs) suppress the production of pro-inflammatory cytokines. This study documents the effects of n-3 PUFAs on cytokines in a group of patients after chronic SCI. METHODS: This double-blind, placebo- controlled trial was designed in 82 (69 males and 13 females) osteoporotic patients with SCI for 4 months. All participants received 1000 mg calcium and 400 IU vitamin D daily. The patients received two MorDHA capsules (435 g of DHA and 65 mg of EPA per day) or two placebo capsules (one with lunch, and the other with dinner) in the treatment and control groups, respectively. Serum interleukins and Dietary intakes were assessed in the beginning and end of the study. Mean difference for each group was compared by using Student's t test. RESULTS: A total of 75 (13 females, 62 males) participants completed the study over 4 months. The supplemented and control groups did not show any difference in their baseline characteristics. There were significant difference neither between two groups at the end of the study nor in each group between beginning and end of the study. CONCLUSINS: MorDHA supplementation for 4 months had no significant effect on inflammatory markers. Although mean difference in all pro-inflammatory cytokines were not significant in both treatment and control groups during the study (P>0.05), the decrease in treatment group was weakly higher that it may be important in point of clinical view.

8.
Indian J Pharmacol ; 44(3): 314-8, 2012 May.
Article in English | MEDLINE | ID: mdl-22701238

ABSTRACT

OBJECTIVES: The aim of this study was to compare systemic effects of high-dose fluticasone propionate (FP) and beclomethasone dipropionate (BDP) via pressurized metered dose inhaler on adrenal and pulmonary function tests. MATERIALS AND METHODS: A total of 66 patients with newly diagnosed moderate persistent asthma without previous use of asthma medications participated in this single blind, randomized, parallel design study. FP or BDP increased to 1 500 µg/d in 62 patients who had not received oral or IV corticosteroids in the previous six months. Possible effects of BDP and FP on adrenal function were evaluated by free cortisol level at baseline and after Synacthen test (250 µg). Fasting plasma glucose and pulmonary function tests were also assessed. Similar tests were repeated 3 weeks after increasing dose of inhaled corticosteroids to 1 500 µg/d. RESULTS: No statistically significant suppression was found in geometric means of cortisol level post treatment in both groups. After treatment in FP group, mean forced expiratory volume in one second (FEV1) and mean forced vital capacity (FVC) values improved by 0.17 l (5.66% ± 13.91, P=0.031) and 0.18 l (5.09% ± 10.29, P=0.010), respectively. Although FEV1 and FVC improved in BDP group but was not statistically significant. Oral candidiasis and hoarseness were observed in 6.5% patients receiving BDP, but hoarseness was found in 3.2% patients in FP group (P=0.288). CONCLUSIONS: The results indicate that safety profiles of high doses of BDP and FP with respect to adrenal function are similar, but FP is more efficacious than that of BDP in improving pulmonary function test.

SELECTION OF CITATIONS
SEARCH DETAIL
...